Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 14 recruiting now full pipeline

Autoimmune Diseases: full-pipeline trial registry

14 of 26 indexed Autoimmune Diseases trials are currently recruiting.

Corpus placement: #627 of 28,707 conditions by registered trial count.

26 US clinical trials · 14 currently recruiting · #627 of 28,707 conditions by registered trial count

Autoimmune Diseases: 26 US clinical trials tracked, 14 recruiting.

Autoimmune Diseases is the subject of 26 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Dragonfly Research, running 1 of these trials.

Enrollment posture brief

Registry condition autoimmune-diseases

OPEN 14 | RECR 54% | LATE 4 | EARLY 5 | RANK #627 | SPON 1

Nearest open-share peer: Advanced Renal Cell Carcinoma (54% recruiting · 13 trials)

Autoimmune Diseases (this)54%Cardiomyopathy38.5%Cancer Survivor26.9%Anaplastic Large Cell Lympho19.2%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Autoimmune Diseases

Autoimmune Diseases lists 14 open slots (54% of 26 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Autoimmune Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Autoimmune Diseases is recruiting above its size-band peers.

    14 of 26 indexed trials (53.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Autoimmune Diseases trials is spread across many organizations.

    Dragonfly Research accounts for 1 of 26 trials (3.8%). 26 distinct sponsors appear on at least one study for this condition label.

  3. Typical Autoimmune Diseases enrolment sits around 131 participants.

    Median target enrolment is 131 among the 26 trials that report a genuine target (sentinel values excluded). 12 of those (46.2%) plan for fewer than 100 participants.

  4. Autoimmune Diseases splits between interventional and observational designs.

    14 interventional and 12 observational studies make up this index (53.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 21Phase 33Phase 41

Open and recent trials

26 total, page 1 of 1

RECRUITING 10,000 participants

Collection and Distribution of Biospecimens for Novel Research Uses

iSpecimen

NCT03848962

RECRUITING Phase 1 5,000 participants

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

Thomas Advanced Medical

NCT04684602

RECRUITING 2,500 participants

IMPACT - AndHealth Autoimmune Research Registry

AndHealth

NCT05883371

RECRUITING NA 1,170 participants

Testimonials and Navigation in Rheumatology

University of Alabama at Birmingham

NCT06469788

RECRUITING 1,000 participants

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

Duke University

NCT03276923

RECRUITING 800 participants

Biologics And Clinical Immunology Cohort at Sinai

Icahn School of Medicine at Mount Sinai

NCT04784364

RECRUITING 500 participants

Rheumatology Diet Study

University of Central Florida

NCT06339957

RECRUITING 500 participants

Ovarian Tissue Cryopreservation for Fertility Preservation

University of Pittsburgh

NCT05875155

RECRUITING 300 participants

Deciphering the Genetic Architecture of Autoimmune Diseases

National Human Genome Research Institute (NHGRI)

NCT06948110

RECRUITING 300 participants

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

TScan Therapeutics

NCT06587828

RECRUITING Phase 1 30 participants

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Arcellx

NCT06626919

RECRUITING NA 30 participants

VNS Prospective Neuromodulation of Immune and Gastrointestinal Systems

University of Louisville

NCT03953768

RECRUITING Phase 4 20 participants

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

Toyos Clinic

NCT06964269

RECRUITING 16 participants

X-linked Moesin Associated Immunodeficiency

Institut National de la Santé Et de la Recherche Médicale, France

NCT06278337

ACTIVE NOT RECRUITING NA 1,325 participants

A Trial of Academic Detailing to Promote Prescribing of Biosimilars

Brigham and Women's Hospital

NCT07221890

ACTIVE NOT RECRUITING Phase 2 34 participants

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Cumberland Pharmaceuticals

NCT02682511

ACTIVE NOT RECRUITING 32 participants

Immuno-Oncology Database and Bioregistry

UNC Lineberger Comprehensive Cancer Center

NCT04656873

COMPLETED Phase 3 433 participants

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Janssen Biotech

NCT01004432

COMPLETED NA 131 participants

Day and Night Closed-loop in Young People With Type 1 Diabetes

Jaeb Center for Health Research

NCT02925299

COMPLETED Phase 1 112 participants

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

Connect Biopharma Australia Pty

NCT04818229

COMPLETED Phase 3 80 participants

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

MediQuest Therapeutics

NCT00419419

COMPLETED 60 participants

Study of Silicone-Associated Connective Tissue Diseases

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT00001330

COMPLETED 48 participants

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

Dragonfly Research

NCT04837651

COMPLETED NA 30 participants

Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients

Cytokind

NCT04818970

COMPLETED Phase 3 10 participants

Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)

National Institute of Mental Health (NIMH)

NCT00001768

COMPLETED Phase 1 1 participants

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

Joseph B. Ciolino, MD

NCT01582880

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1
Phase 3 3
Phase 4 1

Top Sponsors

Named interventions

Most-linked intervention names on Autoimmune Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Topical AmphiMatrix with nitroglycerin (MQX-503) Drug
1 trials
T-Detect COVID T-cell blood test Device
1 trials
Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test Device
1 trials
non Narrow Band ultraviolet B-Band Light Device
1 trials
Narrow Band ultraviolet B-Band Light Device
1 trials
Golimumab 2 mg/kg IV Drug
1 trials
Golimumab 50 mg SC Drug
1 trials
Placebo-matched Moxifloxacin Drug
1 trials

US sites by state

Facility locations filed on Autoimmune Diseases trials. A trial with sites in several states counts in each.

Massachusetts 7 trials
California 7 trials
Maryland 6 trials
Pennsylvania 5 trials
Florida 5 trials
Texas 4 trials
New York 4 trials
North Carolina 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Autoimmune Diseases page

26 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 14 Autoimmune Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Dragonfly Research sponsors the most Autoimmune Diseases trials on record, review their full trial history before evaluating a specific study. See Dragonfly Research's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Autoimmune Diseases condition card totals 26 registered trials; most-linked intervention Topical AmphiMatrix with nitroglycerin (MQX-503); top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.